financetom
Business
financetom
/
Business
/
Update: Northland Power Down 27% as Its Q3 Loss Widens; Cuts Dividend by 40%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Northland Power Down 27% as Its Q3 Loss Widens; Cuts Dividend by 40%
Nov 13, 2025 11:20 AM

01:44 PM EST, 11/13/2025 (MT Newswires) -- (Adds detail and updates shares.)

Northland Power (NPI.TO) shares were last seen down 27% after the renewable power producer overnight Wednesday reported a wider third-quarter loss despite higher revenue and cut its dividend by 40%.

The company a loss attributable to shareholders of $412.67 million, or $1.58 per share, compared to a loss of $178.16 million, or $0.70, in the corresponding year-ago quarter.

Northland attributed the wider loss to higher finance and development costs, a $140-million fair-value charge and a $527-million non-cash impairment charge for its Nordsee One offshore wind facility

Third-quarter revenue from energy sales was $554.5 million compared to $490.5 million in the same quarter of 2024. The consensus estimates compiled by FactSet for revenue was $526.7 million.

Northland also said its board of directors approved a cut to its annual dividend to $0.72 per share from $1.20. The change will be applicable to the payout made Jan. 15, 2026, to shareholders of record on Dec. 31, 2025.

"As part of Northland's strategy, we have assessed growth opportunities in our core markets in Canada and Europe. We see multiple value-accretive opportunities where Northland's capabilities can be deployed to deliver long-term value for shareholders. To provide greater financial flexibility for self-funded growth while maintaining an investment grade balance sheet, the Board of Directors has decided to adjust Northland's dividend to $0.72 per share on an annual basis. We are committed to this sustainable dividend and we look forward to providing our plan and outlook to the market at our upcoming Investor Day," chief executive Christine Healy said.

The company further said that management's 2025 financial outlook remains unchanged from the revised guidance issued on Aug. 13, including expected adjusted EBITDA in the range of $1.2 billion to $1.3 billion and free cash flow per share to be in the range of $1.15 to $1.35.

Northland shares were last seen down $6.81 to $18.26 on the Toronto Stock Exchange.

Price: 18.29, Change: -6.78, Percent Change: -27.04

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Redwire Plans to Appoint Chris Edmunds as Chief Financial Officer
Redwire Plans to Appoint Chris Edmunds as Chief Financial Officer
Oct 7, 2025
08:17 AM EDT, 10/07/2025 (MT Newswires) -- Redwire ( RDW ) said Tuesday it intends to appoint Chris Edmunds as chief financial officer, replacing Jonathan Baliff, who will retire, effective Nov. 30. Edmunds currently serves as the company's chief accounting officer. Baliff will serve as a consultant through December 2026, Redwire ( RDW ) said. The company's shares were up...
Fractyl Health Says Obesity Drug Candidate Shows Weight Loss in Preclinical Trial
Fractyl Health Says Obesity Drug Candidate Shows Weight Loss in Preclinical Trial
Oct 7, 2025
08:17 AM EDT, 10/07/2025 (MT Newswires) -- Fractyl Health ( GUTS ) said Tuesday that new preclinical data from its obesity candidate RJVA-002 showed 30% weight loss in mice after a single dose, with no adverse effects observed. The company said the study used a diet-induced obesity model with humanized GIP receptors and demonstrated a dose-dependent reduction in body weight...
Telomir Says Investigational Therapy Reactivates Tumor Suppressor Genes in Preclinical Models
Telomir Says Investigational Therapy Reactivates Tumor Suppressor Genes in Preclinical Models
Oct 7, 2025
08:17 AM EDT, 10/07/2025 (MT Newswires) -- Telomir Pharmaceuticals ( TELO ) said Tuesday that preclinical results show that its investigational therapy Telomir-1 reactivated two tumor suppressor genes, potentially preventing the spread of cancer and improving responses to chemotherapy. The results showed that the experimental therapy reactivated the MASPIN and RASSF1A genes through DNA methylation reset in prostate cancer models,...
IonQ Closes Vector Atomic Acquisition
IonQ Closes Vector Atomic Acquisition
Oct 7, 2025
08:13 AM EDT, 10/07/2025 (MT Newswires) -- IonQ ( IONQ ) said Tuesday it closed its acquisition of California-based quantum sensing company Vector Atomic. The company said the all-stock deal adds precision atomic clocks, inertial sensors, and synchronization hardware to its computing and networking stack. IonQ ( IONQ ) shares were up over 2% in recent premarket activity. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved